Introduction
============

A significant number of patients who undergo major surgery suffer postoperative complications, many of which may be avoidable \[[@B1],[@B2]\]. The associated health and financial loss is significant, especially considering patients who suffer from postoperative complications suffer long-term morbidity \[[@B3]\]. A significant proportion of patients undergoing surgery suffer from postoperative complications, and identification of this cohort of patients may enable appropriate preventative measures to be taken \[[@B4]\]. Perioperative goal-directed therapy (GDT) aims to match the increased oxygen demand incurred during major surgery, by flow-based haemodynamic monitoring and therapeutic interventions to achieve a predetermined haemodynamic endpoint. When carried out early, in the right patient cohort, and with a clearly defined protocol, GDT has been shown to reduce postoperative mortality and morbidity \[[@B5]\].

Despite this, postoperative GDT is not carried out widely, perhaps due to the lack of evidence for its benefit from large multicenter randomized clinical trials. Scepticism about GDT may exist for a number of reasons: many of the studies performed may be considered outdated; the high mortality rates in some of the studies performed are not representative of current clinical practice; and pulmonary artery catheters (PACs) are used in many of the clinical trials but have been largely superseded by less invasive haemodynamic monitors. A recent meta-analysis has demonstrated that although studies prior to 2000 demonstrate a benefit in mortality, studies con ducted after 2000 demonstrate a significant reduction in complication rates \[[@B5]\]. Furthermore, the reduction in complication rates is significant regardless of the type of haemodynamic monitor used.

We hypothesized that the benefits of GDT are greater in patients who are at higher risk of mortality. We defined risk by the mortality rate of the study population undergoing major surgery. We conducted this meta-analysis to determine if GDT in high-risk surgical patients undergoing major non-cardiac surgery improves postoperative mortality and morbidity, and if this was affected by the mortality risk among the population studied.

Methods
=======

Eligibility criteria
--------------------

We reported only randomized controlled trials, that reported morbidity (complications) and mortality as primary or secondary outcomes. GDT was defined as the term encompassing the use of haemodynamic monitoring and therapies aimed at manipulating haemodynamics during the perioperative period to achieve a predetermined haemodynamic endpoint(s). Studies with GDT started pre-emptively in the perioperative period (24 hours before, intraoperative or immediately after surgery) were included. The GDT must have an explicit protocol, defined as detailed step-by-step instructions for the clinician based on patient-specific haemodynamic data obtained from a haemodynamic monitor or surrogates (for example, lactate, oxygen extraction ratio), and predefined interventions carried out by the clinician in an attempt to achieve the goal(s). Interventions included fluid administration alone or fluids and inotropes together. As the use of inotropic agents was aimed at a specific haemodynamic goal(s) and titrated accordingly, fixed dose studies of inotropes were excluded. Only studies involving adult general surgical populations were included, and studies involving cardiac, trauma and paediatric surgery were excluded.

Information sources
-------------------

A systematic literature search of MEDLINE (via Ovid), EMBASE (via Ovid) and the Cochrane Controlled Clinical trials register (CENTRAL, issue 4 of 2012) was conducted to identify suitable studies. Only articles written in English were considered. Date restrictions were not applied to the CENTRAL and MEDLINE searches. EMBASE was restricted to the years 2009 to2012 \[[@B6]\]. The last search update was in April 2012.

Search strategy
---------------

We included the following search terms: goal-directed therapy, optimization, haemodynamic, goal oriented, goal targeted, cardiac output, cardiac index, oxygen delivery, oxygen consumption, cardiac volume, stroke volume, fluid therapy, fluid loading, fluid administration, optimization, supranormal, lactate and extraction ratio. Search terms were entered into the electronic databases using search strategy methods validated by the Cochrane collaboration (see Box 1 for search strategies used) \[[@B7]\]. In addition to searching electronic databases, previous review articles on the subject were hand-searched for further references.

Methodological quality of included studies
------------------------------------------

Methodological quality of included studies was assessed using criteria described by Jadad and colleagues \[[@B8]\]. The Jadad scale analyzes methods used for random assignment, blinding and flow of patients in clinical trials. The range of possible scores is 0 (lowest quality) to 5 (highest quality).Studies were not excluded based on Jadad scores.

Analysis of outcomes
--------------------

Three investigators independently screened both the titles and abstracts to exclude non-pertinent studies. Relevant full text articles were then retrieved and analysed for eligibility against the pre-defined inclusion criteria. Information from selected studies was extracted using a standardized data collection form. Data were collected independently by three different investigators (GA, NA and CC) and discrepancies resolved by a fourth author (MC).

Hospital mortality was reported in all the included articles and was the primary outcome of our study. Morbidity, expressed as number of patients with complications, was the secondary outcome. Mortality risk groups were based on the definition of the high-risk surgical patient by Boyd and Jackson, such that patients whose risk of mortality was 5 to 19% and ≥20% were classified as high-risk and extremely high-risk, respectively \[[@B9]\]. We therefore performed subgroup analyses based on the control group mortality in each study. We created three subgroups based on the mortality rate of the control group. Mortality rates of 0 to 4.9%, 5 to 19.9%, and ≥20% were considered intermediate, high risk, and extremely high risk, respectively. Mortality and complications were analyzed according to the above subgroups. Studies were also analyzed according to the type of monitor used, type of interventions, the therapeutic goals, and the use of \'supranormal\' physiological goals.

Statistical analysis
--------------------

Dichotomous data outcomes were analysed using the Mantel-Haenszel random effects model and results presented as an odds ratio (OR) with 95% confidence intervals (CI). The meta-analysis was carried out using review manager (\'Revman\') for MAC (version 5.1, Cochrane collaboration, Oxford, UK). Statistical heterogeneity was assessed using the I^2^methodology. When an I^2^value of \>50% was present heterogeneity and inconsistency were considered significant, and when it was \>75% these were considered highly significant \[[@B10]\]. All *P*-values were two-tailed and considered statistically significant if \<0.05.

Results
=======

Included trials
---------------

The search strategy used in this study produced 12,938 potential titles (Figure [1](#F1){ref-type="fig"}). After screening of titles and abstracts, 307 references were identified as relevant to perioperative GDT. After further screening of titles and abstracts against our inclusion criteria, 85 references were retrieved for full text analysis. Detailed full text evaluation excluded 13 studies, as they were not randomized controlled trials \[[@B11]-[@B23]\]. Analysis of the remaining 72 randomized controlled trials produced the following exclusions: studies focusing on fluid management strategies (that is, liberal versus restrictive) \[[@B24]-[@B33]\], use of \'fixed dose\' inotropic agents not titrated to a predetermined goal \[[@B34]-[@B38]\], cardiac surgery \[[@B39]-[@B44]\], trauma \[[@B45]-[@B52]\], paediatric surgery \[[@B53]\] and critically ill medical populations \[[@B54]-[@B62]\]. A study not using protocols to direct application of GDT was also excluded \[[@B63]\]. The quality of the trials was analysed using the Jadad score. The median Jadad score was 3.

![**Flow diagram illustrating search strategy**. RCT, randomised controlled trial.](cc11823-1){#F1}

Description of studies
----------------------

A total of 32 studies were included in the meta-analysis (Table [1](#T1){ref-type="table"}) \[[@B64]-[@B95]\]. These 32 studies included a total of 2,808 patients, 1,438 in the GDT arm and 1,370 in the control treatment arm. Five studies included patients who were considered extremely high risk, 12 included patients who were high risk, and 15 included patients who were intermediate risk. The intermediate-risk, high-risk, and extremely high-risk mortality subgroups included 1,569, 924, and 315 patients, respectively. There were similar numbers of patients in the GDT and control arms. Twenty studies initiated GDT at start of surgery, whilst the other studies initiated GDT before or immediately after surgery.

###### 

Summary of included studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                               Year   Jadad score   Type of surgery                              Number of patients GDT group   Number of patients control group   Type of monitor in GDT group   Intervention type     Goals in GDT group     Goals in control group   Mortality GDT (%)   Mortality control (%)   Complications GDT (%)   Complications control (%)
  ----------------------------------- ------ ------------- -------------------------------------------- ------------------------------ ---------------------------------- ------------------------------ --------------------- ---------------------- ------------------------ ------------------- ----------------------- ----------------------- ---------------------------
  Bender *et al.*\[[@B64]\]           1997   1             Elective vascular/aortic                     51                             53                                 PAC                            Fluid and inotropes   CI ≥ 2.8\              Standard care            1.96                1.9                     13.73                   13.21
                                                                                                                                                                                                                               PAWP 8-14 SVR\                                                                                                      
                                                                                                                                                                                                                               \<1100                                                                                                              

  Benes *et al.*\[[@B65]\]            2010   3             Elective abdominal                           60                             60                                 Flotrac                        Fluid and inotropes   SVV \<10%\             MAP \> 65\               1.67                3.3                     30                      58.33
                                                                                                                                                                                                                               CI ≥2.5                HR \< 100\                                                                                   
                                                                                                                                                                                                                                                      CVP 8-12                                                                                     

  Berlauk *et al.*\[[@B66]\]          1991   2             Peripheral vascular surgery                  68                             21                                 PAC                            Fluid and inotropes   CI ≥2.8\               Standard care            1.47                9.5                     16.7                    42.8
                                                                                                                                                                                                                               PAWP 8-14 SVR\                                                                                                      
                                                                                                                                                                                                                               \<1100                                                                                                              

  Bonazzi\                            2002   2             Elective vascular                            50                             50                                 PAC                            Fluid and inotropes   CI \>3.0\              Standard care            0                   0                       4                       8
  *et al.*\[[@B67]\]                                                                                                                                                                                                           PAWP 10-18\                                                                                                         
                                                                                                                                                                                                                               SVR \<1,450\                                                                                                        
                                                                                                                                                                                                                               DO~2~I \>600                                                                                                        

  Boyd *et al.*\[[@B68]\]             1993   1             Abdominal/vascular                           53                             54                                 PAC                            Fluid and notropes    MAP 80-110\            MAP 80-110\              5.66                22.2                    NS                      NS
                                                                                                                                                                                                                               PAWP 12-14\            PAWP 12-14\                                                                                  
                                                                                                                                                                                                                               SpO~2~\>94%\           SpO~2~\>94%\                                                                                 
                                                                                                                                                                                                                               Hb \>12 DO~2~I \>600   Hb \>12 UO \>0.5 ml/\                                                                        
                                                                                                                                                                                                                                                      kg/h                                                                                         

  Buettner *et al.*\[[@B69]\]         2008   2             Major abdominal or gynaecological            40                             40                                 PiCCO                          Fluids                SPV \<10%\             Standard care            0                   2.5                     NS                      NS
                                                                                                                                                                                                                               HCt \>23%\                                                                                                          
                                                                                                                                                                                                                               Normal clotting                                                                                                     

  Cecconi *et al.*\[[@B70]\]          2011   4             Total hip replacement                        20                             20                                 Flotrac                        Fluid and inotropes   SV change\             Standard care            0                   0                       80                      100
                                                                                                                                                                                                                               DO~2~I \>600                                                                                                        

  Challand *et al.*\[[@B71]\]         2012   5             Major open/laparoscopic colorectal           89                             90                                 OD                             Fluids                SV change              Standard care            5.62                4.4                     33.71                   28.89

  Conway *et al.*\[[@B72]\]           2002   2             Major bowel resection                        29                             28                                 OD                             Fluids                FTc \>0.35\            Standard care            0                   3.6                     17.24                   32.14
                                                                                                                                                                                                                               SV change                                                                                                           

  Donati *et al.*\[[@B73]\]           2007   3             Elective major abdominal/aortic              68                             67                                 CVC                            Fluids                O~2~ER \<27%\          MAP \>80\                2.94                3                       13.24                   40.3
                                                                                                                                                                                                                               MAP \>80\              UO \>0.5\                                                                                    
                                                                                                                                                                                                                               UO \>0.5\              CVP 8-12\                                                                                    
                                                                                                                                                                                                                               CVP 8-12\              Hb \>10                                                                                      
                                                                                                                                                                                                                               Hb \>10                                                                                                             

  Forget *et al.*\[[@B74]\]           2010   2             Major intrabdominal                          41                             41                                 Masimo pulsoximeter            Fluids                PVI \<13%              Standard care            4.88                0                       78.05                   100

  Gan *et al.*\[[@B75]\]              2002   5             Elective general, urological, gynaecologic   50                             50                                 OD                             Fluids                FTc \>0.35\            Increase HR\             0                   0                       42                      76
                                                                                                                                                                                                                               SV change              \>20% baseline\                                                                              
                                                                                                                                                                                                                                                      sBP \<90 or CVP\                                                                             
                                                                                                                                                                                                                                                      \<20% baseline                                                                               

  Harten *et al.*\[[@B76]\]           2008   3             Emergency abdominal                          14                             15                                 Lidco                          Fluids                PPV                    Standard care            7.14                13.3                    50                      26.67

  Jhanji *et al.*\[[@B77]\]           2010   3             Major surgery                                45                             45                                 LiDCO                          Fluids                SV                     CVP standard\            11.11               13.3                    57.58                   66.67
                                                                                                                                                                                                                                                      care                                                                                         

  Lobo *et al.*\[[@B78]\]             2000   3             Major surgery                                19                             18                                 PAC                            Fluid and inotropes   DO~2~I \>600           Standard care            15.79               50                      31.58                   66.67

  Lobo *et al.*\[[@B79]\]             2006   3             Major surgery                                25                             25                                 PAC                            Fluid and inotropes   PWP 12-16\             PAWP 12-16\              8                   28                      16                      52
                                                                                                                                                                                                                               MAP 70-110\            MAP 70-110\                                                                                  
                                                                                                                                                                                                                               HCt \>30%, SAO2\       HCt \>30%\                                                                                   
                                                                                                                                                                                                                               \>94%\                 SaO2 \>94%\                                                                                  
                                                                                                                                                                                                                               UO \>0.5\              UO \>0.5\                                                                                    
                                                                                                                                                                                                                               DO2I \>600                                                                                                          

  Lopes *et al.*\[[@B80]\]            2007   2             Major surgery                                17                             16                                 IBPplus; Dixtal                Fluids                ΔPP \<10%              Standard care            11.76               31.3                    41.18                   75

  Mayer *et al.*\[[@B81]\]            2010   2             Major gastrointestinal surgery               30                             30                                 Flotrac                        Fluid and inotropes   CI \>2.5\              CVP 8-12\                6.67                6.7                     20                      50
                                                                                                                                                                                                                               SVV \<12%              MAP \>65\                                                                                    
                                                                                                                                                                                                                                                      UO \>0.5                                                                                     

  Noblett *et al.*\[[@B82]\]          2006   5             Colorectal                                   51                             52                                 OD                             Fluids                FTc \>0.35\            Standard care            0                   1.9                     1.96                    15.38
                                                                                                                                                                                                                               SV change                                                                                                           

  Pearse *et al.*\[[@B83]\]           2005   3             Major surgery                                62                             60                                 LiDCO                          Fluid and inotropes   DO~2~I \>600           SaO2 ≥94%\               11.29               15                      43.35                   68.33
                                                                                                                                                                                                                                                      Hb \>8\                                                                                      
                                                                                                                                                                                                                                                      Temp \>37°C\                                                                                 
                                                                                                                                                                                                                                                      HR \<100 or \<20\                                                                            
                                                                                                                                                                                                                                                      above baseline\                                                                              
                                                                                                                                                                                                                                                      MAP 60-100\                                                                                  
                                                                                                                                                                                                                                                      CI ≥2.5                                                                                      

  Senagore *et al.*\[[@B84]\]         2009   3             Elective lap colorectal                      42                             22                                 OD                             Fluids                SV response            Standard care            2.38                4.7                     NS                      NS

  Shoemaker *et al.*\[[@B85]\]        1988   2             Major surgery                                28                             60                                 PAC                            Fluid and inotropes   CI \>4.5\              Standard care            3.57                30                      28.5                    50
                                                                                                                                                                                                                               VO2 \>170\                                                                                                          
                                                                                                                                                                                                                               DO2I \>600                                                                                                          

  Sinclair *et al.*\[[@B86]\]         1997   2             Neck of femur repair                         20                             20                                 OD                             Fluids                FTc \>0.35\            Standard care            5                   10                      NS                      NS
                                                                                                                                                                                                                               \                                                                                                                   
                                                                                                                                                                                                                               SV change                                                                                                           

  Szakmany *et al.*\[[@B87]\]         2005   3             Major abdominal                              20                             20                                 PiCCO                          Fluids                ITBV 850-950 ml/m^2^   CVP\                     9.09                5                       NS                      NS
                                                                                                                                                                                                                                                      Standard care                                                                                

  Ueno *et al.*\[[@B88]\]             1998   2             Hepatic resection                            16                             18                                 PAC                            Fluid and inotropes   CI \>4.5\              SpO2 \>95%\              0                   11.1                    0                       27.78
                                                                                                                                                                                                                               VO2 \>170\             Mean PAOP 11-15 mmHg\                                                                        
                                                                                                                                                                                                                               DO2I \>600             Hb \>10                                                                                      

  Valentine *et al.*\[[@B89]\]        1998   3             Aortic                                       60                             60                                 PAC                            Fluid and inotropes   CI \>2.8\              Standard care            5                   1.7                     25                      16.67
                                                                                                                                                                                                                               PAWP 8-15\                                                                                                          
                                                                                                                                                                                                                               SVR \<1100                                                                                                          

  Van Der linden *et al.*\[[@B90]\]   2010   4             Vascular                                     40                             17                                 LiDCO + CVC                    Fluid and inotropes   CI \>2.5               Standard care            7.5                 0                       10                      0

  Venn *et al.*\[[@B91]\]             2002   3             Neck of femur repair                         30                             60                                 OD                             Fluids                FTc \>0.35\            Standard care            10                  6.9                     34.4                    72.4
                                                                                                                                                                                                                               SV change                                                                                                           

  Wakeling *et al.*\[[@B92]\]         2005   3             Colorectal                                   67                             67                                 OD                             Fluids                SV change              Standard care            0                   1.5                     35.82                   56.72

  Wenkui *et al.*\[[@B93]\]           2010   3             Elective GI Cancer                           109                            105                                Lactate                        Fluids                Lactate \<1.6          Standard care            0.92                3.8                     22.94                   33.3

  Wilson *et al.*\[[@B94]\]           1999   4             Major surgery                                92                             46                                 PAC                            Fluid and inotropes   DO2I \>600             Standard care            3.26                17.4                    41.3                    60.87

  Ziegler *et al.*\[[@B95]\]          1997   2             Vascular                                     32                             40                                 PAC                            Fluid and inotropes   PAOP \>12              Standard care            9.38                5                       25                      27.5
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI, cardiac index (ml/minute/m^2^); CVP, central venous pressure (cmH~2~O); CVC, central venous catheter; DO~2~I, oxygen delivery index (ml/minute/m^2^); FTc, corrected flow time; GDT, goal-directed therapy; Hb, haemoglobin (g/dl); Hct, haematocrit (%); HR, heart rate (beats/minute); ITBV, intrathoracic blood volume; VO~2~, oxygen consumption (ml/minute); MAP, mean arterial pressure (mmHg); NS, not stated; O~2~ER, oxygen extraction ratio (%); OD, oesophageal Doppler; PAC, pulmonary artery catheter; PAOP, pulmonary artery occlusion pressure (mmHg); PAWP, pulmonary artery wedge pressure (mmHg); PP, pulse pressure; PPV, pulse pressure variation; PVI, plethysmographic variability index; SAO~2~, aterial oxygen saturation; sBP, systolic blood pressure (mmHg); SpO~2~, oxygen saturation (%); SV, stroke volume (ml); SVR, systemic vascular resistance (dynes-s/cm^5^); SVV, stroke volume variation (%); UO, urine output (ml/kg/h); VO~2~, oxygen consumption (ml/minute).

Mortality
---------

Three studies did not report any deaths in the control or intervention group. All 32 studies included mortality rates (Figure [2](#F2){ref-type="fig"}). Although there was an overall benefit on mortality (OR 0.52, 95% CI 0.36 to 0.74; *P*= 0.003), subgroup analyses revealed that mortality benefit was seen only in studies that included extremely high risk patients (OR 0.20, 95% CI 0.09 to 0.41; *P*\< 0.0001) but not for the intermediate-risk patients (OR 0.83, 95% CI 0.41 to 1.69; *P*= 0.62). There was a trend towards a reduction in mortality in the high risk group (OR 0.65, 95% CI 0.39 to 1.07; *P*= 0.09; Figure [2](#F2){ref-type="fig"}). Further subgroup analyses of mortality as an endpoint revealed that mortality was reduced in the studies using a pulmonary artery catheter (OR 0.3, 95% CI 0.15 to 0.60; *P*= 0.0007), fluids and inotropes as opposed to fluids alone (OR 0.41, 95% CI 0.23 to 0.73; *P*= 0.002), cardiac index or oxygen delivery index as a goal (OR 0.36, 95% CI 0.21 to 0.36; *P*= 0.0003), and a supranormal resuscitation target (OR 0.27, 95% CI 0.15 to 0.47; *P*\< 0.00001) (Table [2](#T2){ref-type="table"}).

![**Effect of goal-directed therapy (GDT) in protocol group versus control group on mortality rate, grouped by control group mortality rates**. CI, confidence interval; M-H, Mantel-Haenszel.](cc11823-2){#F2}

###### 

Mortality by subgroup analysis

                         Number of studies   Number of patients in GDT group   Mortality in GDT group (%)   Number of patients in control group   Mortality in control group (%)   Odds ratio   95% CI       *P*-value
  ---------------------- ------------------- --------------------------------- ---------------------------- ------------------------------------- -------------------------------- ------------ ------------ -----------
  **Risk group**                                                                                                                                                                                             
   Intermediate risk     15                  807                               16 (2.0)                     762                                   17(2.2)                          0.83         0.41-1.69    0.62
   High risk             12                  489                               31 (6.3)                     435                                   45 (10.3)                        0.65         0.39-1.07    0.09
   Extremely high risk   5                   142                               11 (7.7)                     173                                   51 (29.5)                        0.2          0.09-0.41    \<0.0001
  **Fluid/inotropes**                                                                                                                                                                                        
   Fluid                 16                  732                               25 (3.4)                     738                                   38 (5.1)                         0.72         0.42-1.23    0.23
   Fluid + inotrope      16                  706                               33 (4.7)                     632                                   75 (11.9)                        0.41         0.23-0.73    0.002
  **Goal**                                                                                                                                                                                                   
   Supranormal           9                   365                               19 (5.2)                     351                                   65 (18.5)                        0.27         0.15-0.47    \<0.00001
   Normal                23                  1073                              39 (3.6)                     1,019                                 48 (4.7)                         0.80         0.51-1.27    0.35
  **Target**                                                                                                                                                                                                 
   CI/DO~2~I             15                  674                               30 (4.5)                     592                                   73 (12.3)                        0.36         0.21-0.36    0.0003
   FTc/SV                9                   423                               15 (3.5)                     434                                   23 (5.3)                         0.78         0.40-1.52    0.46
   Other                 8                   341                               13 (3.8)                     344                                   17 (4.9)                         0.78         0..35-1.72   0.54
  **Type of monitor**                                                                                                                                                                                        
   PAC                   11                  494                               20 (4.0)                     445                                   62 (13.9)                        0.3          0.15-0.6     0.0007
   ODM                   8                   378                               10 (2.6)                     389                                   17 (4.4)                         0.77         0.35-1.69    0.51
   Other                 13                  566                               28 (4.9                      536                                   34 (6.3)                         0.74         0.43-1.28    0.28

CI, cardiac index (ml/minute/m^2^); DO~2~I, oxygen delivery index (ml/minute/m^2^); FTc, corrected flow time; ODM, oesophageal doppler monitor; PAC, pulmonary artery catheter; SV, stroke volume (ml).

Morbidity
---------

Twenty-seven studies (including 2,477 patients) reported the number of patients with postoperative complications. Meta-analysis of these studies revealed an overall significant reduction in complication rates (OR 0.45, 95% CI 0.34 to 0.60; *P*\< 0.00001; Figure [3](#F3){ref-type="fig"}). Consistent with the mortality benefits, the reduction in morbidity was greatest in the extremely high-risk group (OR 0.27, 95% CI 0.15 to 0.51; *P*\< 0.0001). However, there was also a significant morbidity benefit in the intermediate risk group (OR 0.43, 95% CI 0.27 to 0.67; *P*= 0.0002) and the high-risk groups (OR 0.56, 95% CI 0.36 to 0.89; *P*= 0.01) (Figure [3](#F3){ref-type="fig"}). The reduction in the number of patients suffering postoperative complications was seen across all subgroups, apart from studies that did not use the oxygen delivery index (DO~2~I; ml/minute/m^2^), the cardiac index (CI; ml/minute/m^2^), stroke volume (SV; ml), or corrected flow time (FTc) as a goal (OR 0.48, 95% CI 0.22 to 1.04; *P*= 0.06), although this approached statistical significance (Table [3](#T3){ref-type="table"}).

![**Effect of goal-directed therapy (GDT) in protocol group versus control group on the number of patients with complications, grouped by control group mortality rates**. CI, confidence interval; M-H, Mantel-Haenszel.](cc11823-3){#F3}

###### 

Complications by subgroup analysis

                         Number of studies   Number of patients in GDT group   Patients with complications in GDT group (%)   Number of patients in control group   Patients with complications in control group (%)   Odds ratio   95% CI      *P*-value
  ---------------------- ------------------- --------------------------------- ---------------------------------------------- ------------------------------------- -------------------------------------------------- ------------ ----------- -----------
  **Risk group**                                                                                                                                                                                                                                
   Intermediate risk     13                  727                               194(26.7)                                      698                                   288 (41.3)                                         0.43         0.27-0.67   0.0002
   High risk             10                  449                               149 (33.2)                                     395                                   184 (46.6)                                         0.56         0.36-0.89   0.01
   Extremely high risk   4                   89                                25 (28.1)                                      119                                   67 (56.3)                                          0.27         0.15-0.51   \<0.0001
  **Fluid/inotropes**                                                                                                                                                                                                                           
   Fluid                 12                  610                               198 (32.5)                                     636                                   299 (47.0)                                         0.47         0.30-0.73   0.0007
   Fluid + inotrope      15                  653                               170 (26.0)                                     578                                   240 (41.5)                                         0.44         0.30-0.64   \<0.0001
  **Goal**                                                                                                                                                                                                                                      
   Supranormal           8                   312                               101 (32.4)                                     297                                   153 (51.5)                                         0.34         0.23-0.51   \<0.00001
   Normal                19                  951                               267 (28.1)                                     917                                   386 (42.1)                                         0.51         0.36-0.73   0.0002
  **Target**                                                                                                                                                                                                                                    
   CI/DO2I               14                  621                               162 (26.1)                                     538                                   229 (42.6)                                         0.41         0.28-0.61   \<0.0001
   FTc/SV                7                   361                               118 (32.7)                                     392                                   180 (45.9)                                         0.50         0.30-0.84   0.009
   Other                 6                   281                               88 (31.3)                                      284                                   130 (45.8)                                         0.48         0.22-1.04   0.06
  **Type of monitor**                                                                                                                                                                                                                           
   PAC                   10                  441                               99 (22.4)                                      391                                   129 (33.0)                                         0.49         0.30-0.80   0.005
   ODM                   6                   316                               92 (29.1)                                      347                                   150 (43.2)                                         0.46         0.25-0.86   0.01
   Other                 1!                  506                               177 (35.0)                                     476                                   260 (54.6)                                         0.41         0.26-0.64   0.0001

CI, cardiac index (ml/minute/m^2^); DO~2~I, oxygen delivery index (ml/minute/m^2^); FTc, corrected flow time; ODM, oesophageal doppler monitor; PAC, pulmonary artery catheter; SV, stroke volume (ml)

Discussion
==========

We believe that GDT in high-risk surgical patients is likely to have the greatest benefit if carried out early, in the right patient cohort and with a clearly defined protocol. We performed this meta-analysis to test the hypothesis that patients with the highest perioperative risk gain the greatest benefits from GDT. Studies without clearly defined GDT protocols and studies that initiated GDT late in the postoperative course were therefore excluded from our meta-analysis. Studies were stratified into different risk groups based on the mortality rate of the control group in the study. Heterogeneity in the year of study, patient demographics, type and urgency of surgery, and health care facilities among the different studies are likely to account for the difference in mortality rates.

A reduction in mortality associated with GDT was seen only in the extremely high-risk group of patients (baseline mortality rate of \>20%). A baseline mortality rate of \>20% is unusual in current practice \[[@B4],[@B96]\]; in this sense it is interesting to note that two of five studies with a baseline mortality rate of \>20% were carried out within the past decade. Neither of these studies demonstrated a survival benefit with GDT \[[@B80],[@B97]\]. One of these studies demonstrated a reduction in complication rates \[[@B97]\], whilst the other demonstrated a trend towards a reduction in complication rates \[[@B80]\].

Supranormal physiological targets, targeting DO~2~I or CI, the use of inotropes in addition to fluids, and the use of a PAC were also associated with an improvement in survival. As first demonstrated by Shoemaker and colleagues \[[@B19]\], a supra normal physiological target of global oxygen delivery to ameliorate the oxygen deficit incurred during major surgery is associated with a survival benefit. This is likely to explain the other associations with an improvement in morbidity across all risk groups. The combination of fluids and inotropes is more likely to achieve a supranormal physiological target, as opposed to fluids alone. All eight studies using the oesophageal doppler used fluids alone, reflected by the lack of mortality benefit with the use of FTc or SV as a target. The survival benefit associated with the use of PACs is unlikely to be due to the use of the PACs *per se*. The survival benefit associated with PAC use may be explained by a number of factors. These include the ability to measure and therefore achieve supranormal DO~2~I, and the use of inotropes in addition to fluids in all studies using a PAC.

The reduction in the number of patients suffering postoperative complications was seen across all sub groups, apart from studies that did not use DO~2~I, CI, SV, or FTc as a goal. However, there was a trend towards fewer complications among the GDT cohort in these studies. Goals used by these studies included lactate, pulse pressure variation, plethysmographic variability index, pulmonary artery occlusion pressure, oxygen extraction ratio, and intrathoracic blood volume \[[@B73],[@B74],[@B76],[@B80],[@B87],[@B93],[@B95]\]. Consistent with the trends seen with mortality, the reduction in complication rates was most profound in the extremely high-risk group of patients, protocols with supranormal physiological targets, targeting DO~2I~or CI, and the use of inotropes in addition to fluids. In contrast to the benefits seen in mortality, however, the subgroup using the \'other cardiac output monitors\' had a greater reduction in complication rate than the subgroup using the PAC. This may relate to the complexity and invasive nature of the PAC in comparison to less invasive cardiac output monitors \[[@B98]-[@B100]\].

There remains significant heterogeneity in complication rates among postoperative patients in different centres \[[@B4],[@B96]\]. Although differences in patient demographics are not modifiable, optimal management of the high-risk surgical patient during the perioperative phase may improve overall outcomes. Despite a requirement for an increase in healthcare resources to offer early GDT to high-risk surgical patients, reductions in immediate postoperative complications translate to overall benefits in healthcare costs. Any perceived increase in resource allocation results in a lower patient mortality and morbidity, and therefore a financial saving \[[@B101]\]. Furthermore, reduction in immediate postoperative complications has far-reaching effects, with a potential beneficial effect on long-term survival \[[@B102]\].

This meta-analysis includes trials from 1988 to 2011.As surgical techniques, perioperative care, and patient selection have been refined over these years, the overall mortality of patients has reduced. As such, the applicability of historical trials to current day practice may not be valid. This has recently been evaluated in a meta-analysis of 29 perioperative GDT trials carried out between 1995 and 2008 \[[@B5]\]. There was an approximate halving of mortality rates in the control group every decade (29.5%, 13.5%, 7%). Despite a reduction in mortality rate, the morbidity rate remained constant, with approximately a third of patients experiencing postoperative complications. Perioperative GDT should therefore offer a reduction in complication rates in current practice.

We acknowledge that there is an element of subjectivity in our decision to include trials in this meta-analysis. Many studies were conducted in single centres with limited patient numbers, and not all studies conducted were of a high quality design. This is reflected by the median Jadad score of 3. The effect of study quality on outcomes of GDT trials has been analysed in a recent meta-analysis \[[@B5]\]. Most perioperative GDT trials were singe-centre studies, and only a few were conducted in a double-blind manner. In contrast to the lower quality studies, the higher quality studies (defined as a Jadad score of at least 3) did not demonstrate any benefit in mortality reduction. However, the beneficial effect of reduction in perioperative complication rates was evident irrespective of trial quality.

One of the main limitations of this study is the lack of data on the volume and type of fluids given, and the dose of inotropes used due to variation and inconsistencies in reporting. However, it must be emphasised that the absolute volume of fluids used *per se*is not as important as the way in which fluid is given. Fluid therapy must be titrated against a patient\'s response to a fluid challenge, with the use of haemodynamic monitoring \[[@B103]\]. Such \'goal-directed\' fluid therapy must also be given at the right time, as GDT is not beneficial after complications have already developed \[[@B104],[@B105]\].

One of the other limitations is missing data on the number of patients with complications, due to variations in reporting of complications in the literature, with some studies reporting the number of complications as opposed to the number of patients with complications. Furthermore, we acknowledge that the definitions and coding of complications are likely to vary between studies. We have analysed data extracted from studies, rather than data of individual patients. As some of the studies included were carried out several years ago, obtaining data on individual patients would not have been possible. Despite these limitations, the results remain consistent across many subgroups of patients, and are consistent with other recent meta-analyses, supporting our hypothesis \[[@B5],[@B106]\] and the recent EUSOS study which showed a mortality of 4% \[[@B107]\]. The benefit in terms of reduction of complications of GDT in the intermediate risk group may have implications for the majority of the European surgical population.

Conclusion
==========

Despite heterogeneity in trial quality and design, early GDT among high-risk surgical patients has a significant benefit in reducing rates of complications. There is also an associated reduction in mortality among patients at extremely high risk of perioperative death. GDT is of greatest benefit in patients with the highest risk of mortality.

Note
====

This is part of a series on *Perioperative monitoring*, edited by Dr Andrew Rhodes
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=============

CI: cardiac index (ml/minute/m^2^); DO~2~I: oxygen delivery index (ml/minute/m^2^); FTc: corrected flow time; GDT: goal-directed therapy; PAC: pulmonary artery catheter; SV: stroke volume (ml).

Competing interests
===================

MC: Edwards Lifesciences, LiDCO, Deltex, Applied Physiology, Masimo, Bmeye, Cheetah, Imacor (travel expenses, honoraria, advisory board, unrestricted educational grant, research material). MH: lecture fees from Edwards, Deltex, hutchinson technology and LidCO. AR: honoraria and advisory board for LiDCO. Honoraria for Covidien, Edwards Lifesciences and Cheetah. NA: travel expenses from LiDCO.

###### 

Search strategies

  --------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------
  **1. MEDLINE database (OVID interface): the Cochrane highlysensitive search strategy was used:**\                                       \#12. Allocated randomly.tw.\
  \#1. randomized Controlled Trials as Topic/\                                                                                            \#13.(allocated adj2 random).tw.\
  \#2. randomized controlled trial/\                                                                                                      \#14. Single blind\$.tw.\
  \#3. random Allocation/\                                                                                                                \#15.Double blind\$.tw.\
  \#4. double Blind Method/\                                                                                                              \#16.Placebo\$.tw\
  \#5. single Blind Method/\                                                                                                              \#17.Prospectie study/\
  \#6. clinical trial/\                                                                                                                   \#18. Or/1-17\
  \#7. controlled clinical trial.pt.\                                                                                                     \#19. Casestudy/\
  \#8. randomized controlled trial.pt.\                                                                                                   \#20. Case report.tw.\
  \#9.multicenter study.pt.\                                                                                                              \#21. Abstract report/or letter/\
  \#10.clinical trial.pt.\                                                                                                                \#22. Or/19-21\
  \#11. expClinical Trials as topic/\                                                                                                     \#23. 18 not22\
  \#12. or/1-11\                                                                                                                          \#24. surgery\
  \#13. (clinical adj trial\$).tw.\                                                                                                       \#25. expsurgery/or surgery\
  \#14. ((singl\$ or doubl\$ or treb\$ ortripl\$) adj (blind\$3 or mask\$3)).tw.\                                                         \#26.surg\$\
  \#15. randomly allocated.tw.\                                                                                                           \#27. 24 or 25or 26\
  \#16. (allocated adj2random\$).tw.\                                                                                                     \#28. exp heart/or heart.mp.)and output.mp.\
  \#17. or/13-16\                                                                                                                         \#29. expheart output/or heart output.mp.\
  \#18. 12 or 17\                                                                                                                         \#30. goal directed\
  \#19. casereport.tw.\                                                                                                                   \#31. goaloriented\
  \#20. letter/\                                                                                                                          \#32. goal target\
  \#21.historical article/\                                                                                                               \#33. exp heart index/or heartindex.mp.\
  \#22. or/19-21\                                                                                                                         \#34. exp heart strokevolume/or heart stroke volume.mp.\
  \#23. 18 not 22\                                                                                                                        \#35. expoxygenconsumption/or oxygen consumption.mp.\
  \#24. exp surgery/\                                                                                                                     \#36. oxygendelivery.mp.\
  \#25. surgery.tw.\                                                                                                                      \#37. exp fluidtherapy/\
  \#26.surgery.mp.\                                                                                                                       \#38. fluidadministration.mp\
  \#27. 24 or 25 or 26\                                                                                                                   \#39. fluidloading.mp.\
  \#28. exp goal directed/or goaldirected.tw. or goal directed.mp.\                                                                       \#40. hemodynamic.mp\
  \#29. exp goal oriented/or goaloriented.tw. or goal oriented.mp.\                                                                       \#41. supranormal.mp.\
  \#30 exp goal target/or goal target.tw. or goaltarget.mp.\                                                                              \#42.optimisation.mp.\
  \#31. exp cardiac output/or cardiac output.tw. or cardiac output.mp.\                                                                   \#43. optimization.mp.\
  \#32. exp cardiac index/or cardiac index.tw. or cardiac index.mp.\                                                                      \#44. exp lactate/\
  \#33. exp oxygen delivery/or oxygen delivery.tw. or oxygen delivery.mp.\                                                                \#45. extraction ratio.mp\
  \#34. exp oxygen consumption/or oxygen consumption.tw. or oxygen\                                                                       \#46. \#28 or \#29 or \#30 or \#31 or \#32 or \#33 or \#34 or \#35 or \#36 or \#37 or \#38 or \#39 or \#40 or \#41 or \#42 or \#43 or \#44 or \#45\
  consumption.mp\                                                                                                                         \#47. \#23 and \#27 and \#46\
  \#35. exp cardiac volume/or cardiac volume.tw. or cardiac volume.mp.\                                                                   **3. Cochrane clinical trials database (CENTRAL):**\
  \#36. exp stroke volume/or stroke volume.tw. or strokevolume.mp.\                                                                       \#1. surgery in Trials\
  \#37. exp fluid therapy/or fluid therapy.tw. or fluidtherapy.mp.\                                                                       \#2. surgical\* in Trials\
  \#38. exp fluid loading/or fluid loading.tw. or fluidloading.mp.\                                                                       \#3. surgery\* in Trials\
  \#39. exp fluid administration/or fluid administration.tw. orfluid administration.mp.\                                                  \#4. \#1 OR \#2 OR \#3\
  \#40. exp optimization/or optimization.tw. or optimization.mp.\                                                                         \#5. cardiac near output\* in trials\
  \#41. exp optimisation/or optimisation.tw. oroptimisation.mp.\                                                                          \#6. cardiac near volume\* in Trials\
  \#42. expsupranormal/or supranormal.tw. orsupranormal.mp.\                                                                              \#7. cardiac near index\* in Trials\
  \#43. exp lactate/orlactate.tw. or lactate.mp.\                                                                                         \#8. oxygen near delivery\* in Trials\
  \#44. expextraction ratio/or extraction ratio.tw. orextraction ratio.mp.\                                                               \#9. oxygen near consumption\* in Trials\
  \#45. \#28 or \#29or \#30 or \#31 or \#32 or \#33 or \#34 or \#35or \#36 or \#37 or \#38 or \#39 or \#0or\#41or \#42 or \#43 or \#44\   \#10. supranormal\* in Trials\
  \#46. \#23and \#27 and \#45\                                                                                                            \#11. stroke near volume\* in Trials\
  **2. Embase (OVIDinterface): search restricted to the years2009 to 2012:**\                                                             \#12. fluid near therapy\* in Trials\
  \#1. Clinicaltrial/\                                                                                                                    \#13. fluid near administration\* in Trials\
  \#2. Randomizedcontrolled trial/\                                                                                                       \#14. fluid near loading\* in Trials\
  \#3.Randomization/\                                                                                                                     \#15. extraction near ratio\* in Trials\
  \#4.Single blind procedure/\                                                                                                            \#16. lactate\* in Trials\
  \#5. Double blindprocedure/\                                                                                                            \#17. goal near directed\* in Trials \*\
  \#6. Crossoverprocedure/\                                                                                                               \#18. goal near oriented\* in Trials\
  \#7. Placebo/\                                                                                                                          \#19. goal near target\* in Trials\
  \#8. Randomi?ed controlledtrial\$.tw.\                                                                                                  \#20. Hemodynamic near optimization\* in trials\
  \#9. Rct.tw.\                                                                                                                           \#21. Haemodynamic near optimization \* in trials\
  \#10. Random allocation.tw.\                                                                                                            \#22. Optimization\* in trials\
  \#11.Random allocated.tw                                                                                                                \#23. Optimisation\* in trials\
                                                                                                                                          \#24. \#5 OR \#6 OR \#7 OR \#8 OR \#9 OR \#10 OR \#11 OR \#12 OR \#13 OR \#14 OR \#15 OR \#16 OR \#17 OR \#18 OR \#19 OR \#20 OR \#21 OR \#22 OR \#23\
                                                                                                                                          \#25. \#4 AND\#24
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